Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial
Authors:
- O. VaccaroOVO. Vaccaro
- M. MasulliMMM. Masulli
- E. BonoraEBE. Bonora
- S. Del PratoSPS. Del Prato
- C.B. GiordaCGC.B. Giorda
- A.P. MaggioniA.P. Maggioni
- P. MocarelliPMP. Mocarelli
- A. NicolucciANA. Nicolucci
- A.A. RivelleseARA.A. Rivellese
- S. SquatritoSSS. Squatrito
- G. RiccardiGRG. Riccardi
- 1 November 2012
- journal article
- research article
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 22 (11) , 997-1006
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide studyEuropean Heart Journal, 2011
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up studyDiabetes/Metabolism Research and Reviews, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Mortality within the first 10 years of the disease in type 2 diabetic patientsNutrition, Metabolism and Cardiovascular Diseases, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- The annual incidence of diabetic complications in a population of patients with Type 1 and Type 2 diabetesDiabetic Medicine, 2005
- ThiazolidinedionesNew England Journal of Medicine, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998